Tecnologies per llicenciar

Improving efficacy of cell therapy: Novel set of markers to select active Adipose Stem Cells (ASC)


  • Improvement of cell therapy efficacy by means of a better characterization and selection of cell populations before the cell therapy.
  • The new method improves the immunomodulatory properties of ASCs, which can be useful for autologous therapy in patients with poor ASCs quality and the treatment of different conditions such as Crohn’s disease.


We are currently looking for partners interested in licensing-in the invention. However, other options such as co-development may be taken into consideration.

Intellectual Property

Patent application filed  on 18 September 2017.




Nil Neira
Email: nneira@fbg.ub.es
Tel: +34 934 037 257

Executive summary

Investigators from different top research institutions -with wide expertise in diabetes, stem cell and adipose tissue-related research- gathered together in this project leading to the identification of a novel set of markers of active adipose stem cells (ASC) for improving the efficacy of cell therapy.

The group is currently looking for a license, but other collaborations may be considered.


Cell therapy with mesenchymal stem cells (MSCs) has been described as a promising clinical strategy for regenerative medicine due to their immunosuppressive and tissue repair properties. Adipose tissue is an important source of this cell type (named ASCs) since they are more potent in terms of immunomodulation than their bone marrow counterparts. However, it must be stated that although they are proven to be effective, cell therapy in clinical trials is not as effective as it would be expected. These discrepancies may be due to differences in the donor’s innate immune properties of ASCs as a result of the donor’s metabolic phenotype, a point rarely considered.


This invention consists of a specific panel of markers that allow clinicians select those ASCs samples with the best immunomodulatory characteristics while avoiding those less active or even with pro-inflammatory features.

The adequate selection and characterization of MSC subpopulations is crucial not only to elucidate their true physiological nature but also invaluable for the development of new successful cell therapies.

Furthermore, this invention establishes a specific method that consists of the ex vivo treatment of ASCs to improve their immunomodulatory properties, rendering them good candidates for therapy. This method may be especially useful for autologous therapy in patients with poor ASCs quality (ie. inflammatory diseases such as Crohn’s disease).

Thus, the goal of this technology is to increase the efficacy of ASC therapy by selecting high quality samples before their use in cell therapy. To take a concrete example, these procedures may prove useful to improve Crohn’s disease and some related complications such as perianal fistulas.

Current stage of development

The method has been tested in samples from different patients and has proved its effectiveness in both cell subpopulation characterisation and the improvement of cell immunomodulatory properties.


Comparteix aquest post:
Tags: Life Sciences, Salut i ciències de la vida


Utilitzem cookies de tercers amb finalitats tècniques i analítiques. Si continua navegant vol dir que accepta la nostra política de cookies. Més informació,plugin cookies política de cookies.

Aviso de cookies